Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types.
+ 2 more risks
Excellent balance sheet with limited growth.
Share Price & News
How has Gritstone Oncology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GRTS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GRTS underperformed the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: GRTS underperformed the US Market which returned 8.9% over the past year.
Price Volatility Vs. Market
How volatile is Gritstone Oncology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StAnalysts Are Updating Their Gritstone Oncology, Inc. (NASDAQ:GRTS) Estimates After Its First-Quarter Results
1 month ago | Simply Wall StHere's Why We're Watching Gritstone Oncology's (NASDAQ:GRTS) Cash Burn Situation
2 months ago | Simply Wall StEarnings Update: Gritstone Oncology, Inc. Just Reported And Analysts Are Boosting Their Estimates
Is Gritstone Oncology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GRTS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GRTS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GRTS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: GRTS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GRTS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GRTS is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.7x).
How is Gritstone Oncology forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRTS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GRTS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GRTS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GRTS's revenue (69.9% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: GRTS's revenue (69.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GRTS's Return on Equity is forecast to be high in 3 years time
How has Gritstone Oncology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRTS is currently unprofitable.
Growing Profit Margin: GRTS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GRTS is unprofitable, and losses have increased over the past 5 years at a rate of -38.2% per year.
Accelerating Growth: Unable to compare GRTS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRTS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: GRTS has a negative Return on Equity (-88.94%), as it is currently unprofitable.
How is Gritstone Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: GRTS's short term assets ($112.3M) exceed its short term liabilities ($18.4M).
Long Term Liabilities: GRTS's short term assets ($112.3M) exceed its long term liabilities ($29.2M).
Debt to Equity History and Analysis
Debt Level: GRTS is debt free.
Reducing Debt: GRTS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRTS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GRTS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.2% each year
What is Gritstone Oncology's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GRTS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GRTS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GRTS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GRTS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GRTS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andrew Allen (52yo)
Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph.D., co-founded Gritstone Oncology Inc. and has been its Chief Executive Officer and President since August 2015. Dr. Allen serves as a Director at TCR2 Ther ...
CEO Compensation Analysis
Compensation vs Market: Andrew's total compensation ($USD2.19M) is above average for companies of similar size in the US market ($USD1.33M).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
|Executive VP of Research & Chief Scientific Officer||4.17yrs||US$1.08m||0.86% $2.1m|
|Executive VP & Chief Medical Officer||3.17yrs||US$1.10m||no data|
|Executive VP of Finance & CFO||2.42yrs||US$1.25m||no data|
|Executive VP & CTO||4.67yrs||US$943.05k||0.38% $935.3k|
|Executive VP & General Counsel||0.17yr||no data||no data|
|Senior Vice President of People & Corporate Services||1.25yrs||no data||no data|
|Executive VP & Chief Business Officer||4.58yrs||no data||0.38% $935.3k|
|Executive Vice President of Global Regulatory Affairs & Quality Assurance||4.08yrs||no data||0.027% $65.3k|
|Executive VP of Manufacturing and Technical Operations||0.92yr||no data||no data|
Experienced Management: GRTS's management team is considered experienced (3.6 years average tenure).
|Independent Chairman of the Board||0.083yr||US$102.72k||no data|
|Independent Director||4.75yrs||US$104.45k||no data|
|Independent Director||4.75yrs||US$110.95k||no data|
|Independent Director||4.58yrs||US$105.95k||0.14% $348.2k|
|Independent Director||1.92yrs||US$116.95k||no data|
|Co-Founder & Member of Scientific Advisory Board||3yrs||no data||no data|
|Independent Director||2.75yrs||US$104.95k||no data|
|Co-Founder & Member of Scientific Advisory Board||4yrs||no data||no data|
|Member of Scientific Advisory Board||3yrs||no data||no data|
Experienced Board: GRTS's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.
Gritstone Oncology, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Gritstone Oncology, Inc.
- Ticker: GRTS
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$243.340m
- Shares outstanding: 37.26m
- Website: https://gritstoneoncology.com
Number of Employees
- Gritstone Oncology, Inc.
- 5959 Horton Street
- Suite 300
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GRTS||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 2018|
|2JQ||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2018|
|2JQ||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Sep 2018|
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 05:58|
|End of Day Share Price||2020/06/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.